Intellectus Partners LLC Sells 109 Shares of McKesson Co. (NYSE:MCK)

Intellectus Partners LLC reduced its position in shares of McKesson Co. (NYSE:MCK) by 6.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,478 shares of the company’s stock after selling 109 shares during the quarter. Intellectus Partners LLC’s holdings in McKesson were worth $843,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of MCK. Consolidated Planning Corp increased its stake in McKesson by 35.1% during the 3rd quarter. Consolidated Planning Corp now owns 1,144 shares of the company’s stock valued at $566,000 after purchasing an additional 297 shares in the last quarter. Fiera Capital Corp increased its stake in McKesson by 4.7% during the 3rd quarter. Fiera Capital Corp now owns 847 shares of the company’s stock valued at $419,000 after purchasing an additional 38 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in McKesson during the 3rd quarter valued at about $416,000. SpiderRock Advisors LLC increased its stake in McKesson by 67.3% during the 3rd quarter. SpiderRock Advisors LLC now owns 8,433 shares of the company’s stock valued at $4,170,000 after purchasing an additional 3,391 shares in the last quarter. Finally, Verdence Capital Advisors LLC increased its stake in McKesson by 38.2% during the 3rd quarter. Verdence Capital Advisors LLC now owns 8,698 shares of the company’s stock valued at $4,301,000 after purchasing an additional 2,406 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at McKesson

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of McKesson stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the transaction, the chief executive officer now owns 60,664 shares of the company’s stock, valued at $36,276,465.36. The trade was a 12.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $602.81, for a total transaction of $349,026.99. Following the transaction, the executive vice president now directly owns 1,443 shares in the company, valued at $869,854.83. This represents a 28.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,268 shares of company stock valued at $11,536,378 over the last 90 days. 0.11% of the stock is currently owned by corporate insiders.

McKesson Trading Up 0.5 %

Shares of NYSE MCK opened at $644.92 on Friday. The firm has a 50 day moving average of $600.67 and a 200 day moving average of $567.49. The firm has a market capitalization of $80.82 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $653.92.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Sell-side analysts predict that McKesson Co. will post 32.77 EPS for the current year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s dividend payout ratio is currently 13.00%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MCK. Wells Fargo & Company raised their price objective on shares of McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. Mizuho started coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 price target for the company. StockNews.com lowered shares of McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Citigroup reduced their price target on shares of McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Bank of America reduced their price target on shares of McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $645.79.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.